Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions

Fig. 2

Comparison of the Ki67 expression score and EZH2 expression between primary and metastatic lesions. The mean and standard deviation score of (a) Ki67 expression in primary lesions was 2.74 ± 0.92, and in metastatic lesions was 3.10 ± 0.97. The mean and standard deviation score of (b) EZH2 expression in primary lesions was 3.56 ± 1.34, and in metastatic lesions was 4.26 ± 1.08

Back to article page